GlassScriptPhysician profile
Dale M Bearman
NPI 1457348377
$2,098.55
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $245 · 2021: $431 · 2022: $500 · 2023: $406 · 2024: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.08 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.68 | 2019-2023 | Lo Loestrin Fe, Liletta, Orilissa |
| Astellas Pharma US INC | $325.34 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $161.18 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.19 | 2019-2022 | |
| Hologic Sales and Service, LLC | $113.08 | 2019-2024 | Aptima |
| Aspira Women'S Health INC | $92.87 | 2022 | |
| Coopersurgical, INC. | $88.00 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Myovant Sciences INC. | $83.64 | 2021 | |
| Exeltis, USA INC. | $83.07 | 2020-2024 | Slynd |
| Avion Pharmaceuticals | $76.01 | 2019-2022 | |
| Millicent US INC | $64.52 | 2024 | Intrarosa |
| Evofem Biosciences, INC. | $59.23 | 2022-2023 | Phexxi |
| Therapeuticsmd, INC. | $39.40 | 2019 | |
| Allergan, INC. | $36.89 | 2019 | |
| Mayne Pharma Commercial LLC | $33.03 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $32.00 | 2021 | |
| Organon LLC | $29.86 | 2022-2024 | |
| Amgen INC. | $28.74 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $27.37 | 2021 | |
| Amag Pharmaceuticals, INC. | $26.76 | 2019 | |
| Shield Therapeutics INC | $25.60 | 2023 | Accrufer |
| Roche Diagnostics Corporation | $24.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.49 | 2022 | |
| Agile Therapeutics, INC. | $22.98 | 2022 | |
| Convatec INC. | $19.40 | 2021 | |
| Olympus America INC. | $18.90 | 2024 | 4k Camera Head |
| Sumitomo Pharma America, INC. | $18.89 | 2024 | Myfembree |
| Merck Sharp & Dohme LLC | $18.00 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.26 | 2019 | |
| Shire North American Group INC | $16.32 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Bearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.